MRK AI Stock Analysis – Buy, Hold, or Avoid?
Merck & Co., Inc. (MRK)
Merck (MRK) offers a compelling blend of robust fundamentals, fair valuation, and technical strength, with a strong pipeline and resilient market position supporting further upside. While near-term risks from patent expirations and regulatory pressures exist, the company’s innovation engine and recent acquisitions provide credible offsets. The stock is attractive for long-term investors, with tactical opportunities for traders as it approaches key technical levels.
Fundamentals
Merck & Co. (MRK) demonstrates robust financial health, solid earnings momentum, and strong profitability, bolstered by continued top-line expansion and margin improvement. The company's performance in recent quarters has consistently surpassed expectations, supporting a favorable investment outlook. While valuation is near peer averages, MRK's defensive healthcare profile and pipeline strength continue to offer support for further upside.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
4.97% YoY
Q4 2025
Net Income
-20.84% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.4B | 17.3B | 15.8B | 15.5B | 15.6B | 16.7B | 16.1B | 15.8B |
| Revenue Growth YoY | +4.97% | +3.72% | -1.90% | -1.56% | +6.79% | +4.35% | +7.16% | +8.89% |
| Net Income | 3.0B | 5.8B | 4.4B | 5.1B | 3.7B | 3.2B | 5.5B | 4.8B |
| Net Income Growth YoY | -20.84% | +83.24% | -18.85% | +6.66% | +405.30% | -33.47% | +191.30% | +68.81% |
| EPS | $1.19 | $2.32 | $1.77 | $2.02 | $1.48 | $1.25 | $2.15 | $1.88 |
| EPS Growth YoY | -19.59% | +85.60% | -17.67% | +7.45% | +408.33% | -33.16% | +191.49% | +69.37% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.71% | 77.69% | 77.50% | 77.98% | 75.50% | 75.51% | 76.76% | 77.56% |
| Operating Margin | 53.27% | 37.94% | 35.13% | 38.23% | 27.83% | 23.92% | 38.03% | 36.51% |
| Net Margin | 18.07% | 33.49% | 28.01% | 32.71% | 23.96% | 18.95% | 33.86% | 30.19% |
| Return on Equity (ROE) | 5.63% | 11.16% | 9.04% | 10.51% | 8.08% | 7.09% | 12.52% | 11.80% |
| Return on Assets (ROA) | 3.34% | 6.24% | 5.48% | 6.54% | 4.73% | 4.01% | 7.32% | 7.10% |
Technical Analysis
MRK is currently in a strong uptrend characterized by a golden cross and price positioned comfortably above the 50 and 200 SMAs. Momentum is neutral according to the RSI, and although the ADX indicates a weak trend strength, the overall technical picture supports continued upward movement within an advancing phase.
No extreme reading
Price in uptrend
Range-bound market
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Merck & Co. (MRK) demonstrates robust financial health, solid earnings momentum, and strong profitability, bolstered by continued top-line expansion and margin improvement. The company's performance in recent quarters has consistently surpassed expectations, supporting a favorable investment outlook. While valuation is near peer averages, MRK's defensive healthcare profile and pipeline strength continue to offer support for further upside.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$2.04
Estimated
$2.01
Surprise
+$0.03
Surprise %
+1.49%
Revenue
Actual
$16.4B
Estimated
$16.2B
Surprise
+$200.92M
Surprise %
+1.24%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $2.04 | $2.58 | $2.13 | $2.22 | $1.72 | $1.57 | $2.28 | $2.07 |
| EPS (Estimated) | $2.01 | $2.36 | $2.03 | $2.13 | $1.85 | $1.50 | $2.15 | $1.88 |
| EPS Surprise | +$0.03 | +$0.22 | +$0.10 | +$0.09 | -$0.13 | +$0.07 | +$0.13 | +$0.19 |
| % Diff | +1.5% | +9.3% | +4.9% | +4.2% | -7.0% | +4.7% | +6.0% | +10.1% |
| Revenue | ||||||||
| Revenue (Actual) | $16.4B | $17.28B | $15.81B | $15.53B | $15.62B | $16.66B | $16.11B | $15.78B |
| Revenue (Estimated) | $16.2B | $16.98B | $15.86B | $15.34B | $15.48B | $16.47B | $15.87B | $15.21B |
| Revenue Surprise | +$200.92M | +$297.85M | -$58.53M | +$190.13M | +$141.31M | +$183.35M | +$242.4M | +$569.92M |
| % Diff | +1.2% | +1.8% | -0.4% | +1.2% | +0.9% | +1.1% | +1.5% | +3.7% |
Valuation
Merck (MRK) presents a solid valuation profile with a balanced blend of moderate growth, strong profitability, and industry-aligned multiples. The stock trades near its 52-week high with generally positive sentiment, supported by pipeline advancements and recent acquisitions. While valuation multiples are mostly fair and in line with sector norms, some metrics suggest undervaluation relative to peers and intrinsic value models.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 22.11 | 9.06 | 11.19 | 11.12 | 16.88 | 22.85 | 14.85 | 17.42 |
| Price to Sales | 15.98 | 12.14 | 12.54 | 14.54 | 16.18 | 17.32 | 20.12 | 21.03 |
| Price to Book | 4.98 | 4.04 | 4.04 | 4.67 | 5.46 | 6.48 | 7.44 | 8.22 |
| Enterprise Value to EBITDA | 68.66 | 28.31 | 35.11 | 34.46 | 48.78 | 55.67 | 47.07 | 51.81 |
| Enterprise Value to Revenue | 18.17 | 13.48 | 14.27 | 16.23 | 17.78 | 18.74 | 21.76 | 22.85 |
Sentiment & Analyst Ratings
Merck & Co. (MRK) sentiment currently reflects cautious optimism supported by recent clinical progress, regulatory approvals, and acquisition activity that bolster its pipeline. Although the company’s 2026 earnings guidance came in below Wall Street expectations and concerns linger about patent expirations impacting future sales, analyst ratings lean positively with a growing bullish stance.
Analyst Recommendations
Risk Assessment
Merck & Co. presents a moderately robust financial profile with adequate liquidity and manageable debt levels, supported by its dominant oncology franchise. However, significant risks loom from the upcoming 2028 patent expiration of Keytruda, potential pricing pressures from regulatory acts, and dependency on a concentrated revenue stream. While pipeline expansion and strategic acquisitions aim to mitigate these risks, execution uncertainties and competitive threats increase the investment risk profile.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.54 | 1.66 | 1.42 | 1.41 | 1.36 | 1.36 | 1.47 | 1.25 |
| Quick Ratio | 1.30 | 1.44 | 1.17 | 1.16 | 1.15 | 1.15 | 1.22 | 0.99 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.96 | 0.80 | 0.72 | 0.72 | 0.83 | 0.86 | 0.87 | 0.85 |
| Debt-to-Assets | 0.37 | 0.32 | 0.30 | 0.30 | 0.33 | 0.32 | 0.34 | 0.32 |
Liquidity Assessment
Current Ratio: 1.54(Strong)
Quick Ratio: 1.30(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.96(Moderate)
Debt-to-Assets: 0.37(Moderate)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about MRK
AI Answers: Common Questions About MRK
Get AI-powered answers to the questions investors ask most about Merck & Co., Inc.
MRK is a good buy at current levels ($121.42), trading at a P/E of 16.68 (below peer average) and near its 52-week high, with strong earnings growth (EPS up 8% YoY) and expanding margins (gross margin 81%). Technicals support further upside, and the valuation is fair given the pipeline and profitability.
There is no strong case to sell MRK now unless your thesis has changed or you are highly risk-averse to the 2028 patent cliff; fundamentals remain strong, technicals are bullish, and sentiment is improving. Consider trimming only if the price fails to break above $125.14 or if negative news emerges.
The biggest risks are the 2028 Keytruda patent expiration (potential for major revenue decline), regulatory pricing pressures (Medicare negotiations, Inflation Reduction Act), and revenue concentration in oncology. Debt levels are moderate (debt-to-equity <1.0, debt/assets ~37%), and liquidity is strong (current ratio 1.54).
Technical resistance is at $125.14 (52-week high) with upside target near $130 on breakout; support is at $118.60 (50 SMA) and $97.44 (200 SMA). Analyst upgrades and sentiment suggest a medium-term target in the $125–$130 range if pipeline momentum continues.
MRK is fairly valued with a P/E of 16.68 (below peer average), price-to-sales and EV/EBITDA in line with sector norms, and no signs of overvaluation. The stock offers moderate upside given its growth and profitability profile.
MRK is fundamentally strong, with double-digit revenue growth (13.1% YoY), expanding margins (gross margin 81%, net margin 28%), high ROE (22%), and a robust balance sheet (current ratio 1.54, moderate leverage). Growth is organic and earnings quality is high.
Technical analysis is bullish: price is above both 50 and 200 SMAs (golden cross), RSI is neutral at 57 (no overbought risk), and the next resistance is $125.14–$130. Support is at $118.60, offering a favorable risk/reward for new entries.
Key catalysts include upcoming earnings, new product launches (notably in oncology), positive clinical trial data, and regulatory approvals. Watch for updates on the Terns Pharmaceuticals acquisition, pipeline progress, and any news on Keytruda’s exclusivity.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.